HODGKIN'S DISEASE AND HIV INFECTION (HD-HIV): A REPORT OF 92 PATIENTS FROM THE GICAT (ITALIAN COOPERATIVE GROUP ON AIDS AND TUMORS), WITH EMPHASIS ON PROSPECTIVE STUDY WITH COMBINED CHEMOTHERAPY (CT) AND ZIDOVUDINE (AZT) IN 16 PATIENTS (MEETING ABSTRACT) NLM AIDSLINE Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


HODGKIN'S DISEASE AND HIV INFECTION (HD-HIV): A REPORT OF 92 PATIENTS FROM THE GICAT (ITALIAN COOPERATIVE GROUP ON AIDS AND TUMORS), WITH EMPHASIS ON PROSPECTIVE STUDY WITH COMBINED CHEMOTHERAPY (CT) AND ZIDOVUDINE (AZT) IN 16 PATIENTS (MEETING ABSTRACT)

Proc Annu Meet Am Soc Clin Oncol; 11:A2 1992. Unique Identifier : AIDSLINE ICDB/92680733
Tirelli U; Errante D; Vaccher E; Spina M; Gastaldi R; Rizzardini G; Mandelli F; Milo D; Nosari AM; Rossi G; et al; Centro di Riferimento Oncologico, Aviano, Italy

Abstract: Between November 1986 and June 1991, 92 patients (pts; 84 M, 8 F) with HD-HIV were seen by the GICAT. In accordance with the epidemiology of HIV infection in Italy, 83% were IVDU, 8% homosexual men, 5% IVDU + homosexual and 4% heterosexuals. At diagnosis of HD-HIV, 11% of pts had AIDS, 23% ARC, 28% PGL and 24% were asymptomatic; median CD4 count was 265/mm3. LP subtype was diagnosed in 2%, NS in 25%, MC in 50% and LD in 22% of pts; 28% and 50% were Stage III and IV, respectively. 44 pts were treated with MOPP or MOPP + ABVD +/- RT (AZT was not given) with CR in 50% and PR in 45% of pts. Median survival was 16 mo. 61% of pts developed opportunistic infections (OI) during therapy or follow-up. MOPP + ABVD seemed better tolerated than MOPP alone. Between March 1989 and March 1991, 16 consecutive previously untreated pts were enrolled in a prospective study with combined CT and AZT. Pts were stratified in two groups and treated accordingly. Group A: pts with PS less than 3 and without OI received epirubicin 70 mg/m2 iv day (d) 1, bleomycin 10 mg/m2 iv d 1 and vinblastine 6 mg/m2 iv d 1 (EBV); Group B: pts with PS greater than or equal to 3 and/or OI received a 50% reduced dose of epirubicin and vinblastine and full dose of bleomycin. Courses were repeated every 21 d for 6 cycles. AZT was given at the dose of 500 mg/d per os from the beginning of CT in group B and after the third cycle in group A. Clinical characteristics were comparable to that of the overall group; median CD4 count was 166/mm3. The median number of cycles administered was 6 (3-6). We observed 7/16 (44%) CR (6/11 in the group A), and 6/16 (38%) PR (4/11 in the group A). A CD4+ cell count greater than 150/mm3 was not significantly related to the achievement of CR. 1/13 pt developed OI during CT or follow-up. We did observe an improvement of HIV markers under CT + AZT: the median CD4 count after therapy was 203/mm3, while none of the 9 pts with a negative Ag p24 prior to therapy became positive. Toxicity was moderate with grade 3-4 leukopenia in 8 pts. The median survival was 10.5 mo. In conclusion, these preliminary results reveal the feasibility of the combination of EBV regimen and AZT. Objective response rate seems similar to that previously observed within the GICAT for pts receiving standard CT, but only one OI occurred and this compares favorably with that observed in pts treated with standard CT without AZT.
Keywords: Acquired Immunodeficiency Syndrome/*COMPLICATIONS/*DRUG THERAPY/ ETIOLOGY Antigens, CD4/ANALYSIS Antineoplastic Agents, Combined/*THERAPEUTIC USE AIDS-Related Complex/*COMPLICATIONS/*DRUG THERAPY Bleomycin/ADMINISTRATION & DOSAGE Dacarbazine/ADMINISTRATION & DOSAGE Doxorubicin/ADMINISTRATION & DOSAGE Drug Administration Schedule Female Hodgkin's Disease/*COMPLICATIONS/*DRUG THERAPY/PATHOLOGY Homosexuality Human HIV Infections/*COMPLICATIONS/*DRUG THERAPY/ETIOLOGY Male Mechlorethamine/ADMINISTRATION & DOSAGE Neoplasm Staging Prednisone/ADMINISTRATION & DOSAGE Procarbazine/ADMINISTRATION & DOSAGE Sex Behavior Vincristine/ADMINISTRATION & DOSAGE Zidovudine/*THERAPEUTIC USE CLINICAL TRIAL ABSTRACT MULTICENTER STUDY

KWDacquiredimmunodeficiencysyndrome/KWDcomplications/KWDdrugtherapy/etiologyantigens,cd4/analysisantineoplasticagents,combined/KWDtherapeuticuseaids-relatedcomplex/KWDcomplications/KWDdrugtherapybleomycin/administration&dosagedacarbazine/administration&dosagedoxorubicin/administration&dosagedrugadministrationschedulefemalehodgkin'sdisease/KWDcomplications/KWDdrugtherapy/pathologyhomosexualityhumanhivinfections/KWDcomplications/KWDdrugtherapy/etiologymalemechlorethamine/administration&dosageneoplasmstagingprednisone/administration&dosageprocarbazine/administration&dosagesexbehaviorvincristine/administration&dosagezidovudine/KWDtherapeuticuseclinicaltrialabstractmulticenterstudy
921130
M92B0906

Copyright © 1992 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .